Zoetis Inc (NYSE:ZTS) Receives Average Rating of “Buy” from Brokerages

Zoetis Inc (NYSE:ZTS) has been assigned an average rating of “Buy” from the seventeen research firms that are currently covering the firm, MarketBeat reports. Eight investment analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $130.43.

A number of research firms have recently weighed in on ZTS. Bank of America reissued a “hold” rating and issued a $125.00 price target on shares of Zoetis in a research note on Thursday, December 5th. ValuEngine cut Zoetis from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Credit Suisse Group set a $138.00 target price on Zoetis and gave the stock a “buy” rating in a report on Friday, October 11th. Morgan Stanley increased their target price on Zoetis from $100.00 to $136.00 and gave the stock an “equal weight” rating in a report on Monday, September 30th. Finally, Raymond James initiated coverage on Zoetis in a report on Thursday, January 9th. They set a “market perform” rating for the company.

In related news, CEO Juan Ramon Alaix sold 50,000 shares of Zoetis stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $119.13, for a total transaction of $5,956,500.00. Following the completion of the transaction, the chief executive officer now owns 146,013 shares in the company, valued at $17,394,528.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Glenn David sold 4,440 shares of Zoetis stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $120.02, for a total value of $532,888.80. Following the transaction, the chief financial officer now owns 16,728 shares of the company’s stock, valued at approximately $2,007,694.56. The disclosure for this sale can be found here. Insiders sold a total of 123,917 shares of company stock valued at $14,797,192 in the last 90 days. 0.29% of the stock is owned by corporate insiders.

Institutional investors have recently bought and sold shares of the stock. Prestige Wealth Management Group LLC acquired a new stake in shares of Zoetis in the second quarter valued at approximately $27,000. Tarbox Family Office Inc. raised its position in shares of Zoetis by 74.4% in the third quarter. Tarbox Family Office Inc. now owns 218 shares of the company’s stock valued at $27,000 after buying an additional 93 shares in the last quarter. Tradewinds Capital Management LLC acquired a new stake in shares of Zoetis in the third quarter valued at approximately $31,000. Corbenic Partners LLC acquired a new stake in shares of Zoetis in the fourth quarter valued at approximately $31,000. Finally, Atlas Capital Advisors LLC acquired a new stake in shares of Zoetis in the third quarter valued at approximately $33,000. Institutional investors and hedge funds own 89.96% of the company’s stock.

Shares of ZTS stock traded down $0.01 during trading hours on Thursday, reaching $138.53. The company had a trading volume of 763,374 shares, compared to its average volume of 1,589,748. The company has a 50 day moving average of $128.82 and a 200 day moving average of $123.44. The company has a debt-to-equity ratio of 2.47, a current ratio of 4.39 and a quick ratio of 3.02. The firm has a market cap of $65.85 billion, a price-to-earnings ratio of 44.26, a P/E/G ratio of 2.98 and a beta of 0.81. Zoetis has a 1-year low of $82.26 and a 1-year high of $139.00.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.94 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.06. The company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.58 billion. Zoetis had a return on equity of 70.78% and a net margin of 23.76%. The firm’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.83 EPS. As a group, sell-side analysts forecast that Zoetis will post 3.6 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Friday, January 17th will be issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.58%. The ex-dividend date of this dividend is Thursday, January 16th. This is a boost from Zoetis’s previous quarterly dividend of $0.16. Zoetis’s dividend payout ratio is 21.09%.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Story: Coverage Ratio

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply